We are Sorry, This Page doesn't Exist
Sage drug still differentiated despite positive Axsome data, says Piper Jaffray
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
BioMarin shares gain on positive dwarfism drug data
Shares of BioMarin Pharmaceutical Inc. are up 2.8% in morning trading .....»»
Epizyme announces "positive, mature data" for Phase 2 trial of tazemetostat
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Principia Biopharma announces "consistent positive data" for PRN1008
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Cassava stock is up on Alzheimer"s data
Shares of Cassava Sciences Inc. jumped 24% on positive data from a mid-stage trial for its experimental Alzheimer's disease drug, PTI-125. The data, which .....»»
ChemoCentryx announces "positive" topline data from Phase III avacopan trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Novartis to pay $9.7 billion in latest bet on new technology
Novartis AG agreed to buy Medicines Co. and its promising heart drug for $9.7 billion, the latest move in the Swiss drugmaker’s push to amass novel treatments for complex conditions......»»
Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker
Swiss drugmaker Novartis is betting on heart drug prospect inclisiran in a $9.7 billion takeover of The Medicines Co as it challenges cardiovascular medicines from Amgen Inc , Sanofi and Regeneron Pharmaceuticals ......»»
Biofourmis teams up with Novartis to commercialize a digital therapeutics platform for heart failure patients
This story was delivered to Business Insider Intelligence Digital Health.....»»
AstraZeneca says data shows Farxiga reduces risks in heart failure patients
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Akebia announces "positive" data from two Phase 3 vadadustat studies
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
AstraZeneca says new Farxiga data shows reduced worsening of heart failure
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Boston Scientific announces "positive" data for Ranger balloon, Eluvia stent
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Zogenix announces new data for investigational drug Fintepla for seizures
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Hepion Pharmaceuticals stock soars premarket-leading volume after positive data on liver disease treatment
Shares of Hepion Pharmaceuticals Inc. soared 45% in very active premarket trading Thursday, after the biopharmaceutical company published data showing potential for its CRV431 to be a drug candidate for liver disease tre.....»»
Principia announces "positive" data from Phase 2 trial, says H.C. Wainwright
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Abbott announces outcomes data for device to repair leaky Tricuspid heart valves
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Novartis executive sold shares before drug data manipulation made public
An unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shares less than three weeks before the U.S. Food and Drug Administration (FDA) announced data from tests of its gene therapy Zolgensma had been manipulated......»»
Novartis replaces top scientists at Avexis after drug data manipulated
Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than $2 million......»»
Lilly"s Psoriasis Drug Found Superior To J&J"s Tremfya In Phase 4 Study
Eli Lilly And Co (NYSE: LLY) reported positive data for its plaque psoriasis drug Tuesday in a head-to-head comparison study with Johnson & Johnson (NYSE: JNJ)'s Janssen unit's Tremfya. read more.....»»